Biophan CEO to Speak at Bay Area Biotechnology and Healthcare Investor Forum.

ROCHESTER, N.Y. -- CEO Michael Weiner to Highlight Company's Innovations in Nanotechnology and Biomedicine for Investors

Biophan Technologies, Inc (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that its CEO Michael Weiner will present at the Bay Area Biotechnology and Healthcare Forum in Foster City, California on December 7, 2004.

Mr. Weiner will deliver his comments to an audience of biotechnology investors and other members of the biotechnology industry community. Other presenters at the Forum include Wall Street industry analysts and top executives of key biotechnology companies. The conference, organized by Informed Investors Forums, is sponsored by The Wall Street Journal, Barron's and others.

Mr. Weiner will outline some of Biophan's recent proprietary research and development initiatives using nanotechnologies and other patented anti-antenna procedures to enhance the safety and compatibility of implanted medical devices in the Magnetic Resonance Imaging (MRI) environment. He will also describe market opportunities for Biophan's proprietary technologies and solutions in several multi-billion-dollar areas of the health care sector.

"I'm looking forward to illustrating for this audience the latest achievements from Biophan in the development of our important nanotechnology-based biomedical solutions," Mr. Weiner said. "Biophan is standing at the forefront of the next generation of biomedical science. This forum is an excellent opportunity to highlight for investors the impact that our science has for practitioners and patients, and to demonstrate how our technological innovations and proprietary solutions advance the safety and efficacy of MRI across a wide spectrum of diagnostic and surgical procedures."

About Informed Investors Forums

Founded in 1993, Informed Investors offers a conduit for companies to present their IR message through industry specific forums directly filters. It gives companies the opportunity to provide the transparency investors are seeking. The forums are conducted both over the Internet and in-person through onsite investor conferences. For more information, visit http://www.informedinvestors.com/index.asp and, under "On-site Forums," select "December 7, 2004 Bay Area Biotechnology and Healthcare Forum - Foster City, CA."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending, or allowed. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit http://www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.